Want to see ABVC full AI Analyst Report?
ABVC Stock Chart & Stats
$1.04
$0.03(2.88%)
At close: 4:00 PM EDT
$1.04
$0.03(2.88%)
Day’s Range― - ―
52-Week Range$0.88 - $3.40
Previous Close$1.07
Volume153.44K
Average Volume (3M)95.05K
Market Cap
$27.09M
Enterprise Value$57.74
Total Cash (Recent Filing)$202.51K
Total Debt (Recent Filing)$2.73M
Price to Earnings (P/E)―
Beta1.63
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding26,554,365
10 Day Avg. Volume116,541
30 Day Avg. Volume95,045
Financial Highlights & Ratios
PEG Ratio0.76
Price to Book (P/B)4.46
Price to Sales (P/S)0.00
P/FCF Ratio-16.59
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.3
Revenue Forecast (FY)$35.28M
Bulls Say, Bears Say
Bulls Say
Clinical-stage PipelineABVC's focus as a clinical-stage biopharma in CNS and oncology provides a durable business model driven by clinical milestones. Successful data can enable regulatory paths or partnering/licensing deals, which are structural value drivers less sensitive to short-term market moves.
Improving Cash BurnA substantial reduction in operating cash burn to roughly -$0.06M TTM signals better expense control and extends runway. If sustained, this durable improvement lowers near-term financing pressure and reduces dilution risk, improving the company’s ability to execute clinical programs.
Planned BioKey DistributionThe planned distribution of BioKey shares is a structural corporate action to separate assets. A completed distribution could simplify ABVC’s capital structure, unlock subsidiary value and focus management on core programs, materially affecting strategic optionality over months.
Bears Say
Persistent Net LossesConsistent, sizable net losses erode equity and limit reinvestment capacity. Negative returns on equity and repeated losses are structural constraints that increase funding needs, impair long-term sustainability, and raise execution risk for completing clinical development.
Chronic Negative Cash FlowPersistent negative operating and free cash flow forces reliance on external financing. This structural cash-consumption pattern elevates liquidity risk, can dilute shareholders over time, and makes sustained clinical development contingent on successful funding or partnerships.
Minimal Revenue BaseAn effectively zero TTM revenue base and small historical sales mean the company lacks commercial scale. Without recurring revenue, margins remain driven by R&D and SG&A, keeping profitability structurally negative until commercialization or major partnering occurs.
ABVC BioPharma News
ABVC FAQ
What was ABVC BioPharma, Inc.’s price range in the past 12 months?
ABVC BioPharma, Inc. lowest stock price was $0.88 and its highest was $3.40 in the past 12 months.
What is ABVC BioPharma, Inc.’s market cap?
ABVC BioPharma, Inc.’s market cap is $27.09M.
When is ABVC BioPharma, Inc.’s upcoming earnings report date?
ABVC BioPharma, Inc.’s upcoming earnings report date is Nov 16, 2026 which is in 96 days.
How were ABVC BioPharma, Inc.’s earnings last quarter?
ABVC BioPharma, Inc. released its earnings results on Mar 27, 2026. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is ABVC BioPharma, Inc. overvalued?
According to Wall Street analysts ABVC BioPharma, Inc.’s price is currently Overvalued.
Does ABVC BioPharma, Inc. pay dividends?
ABVC BioPharma, Inc. does not currently pay dividends.
What is ABVC BioPharma, Inc.’s EPS estimate?
ABVC BioPharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ABVC BioPharma, Inc. have?
ABVC BioPharma, Inc. has 26,554,365 shares outstanding.
What happened to ABVC BioPharma, Inc.’s price movement after its last earnings report?
ABVC BioPharma, Inc. reported an EPS of -$0.11 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.66%.
Which hedge fund is a major shareholder of ABVC BioPharma, Inc.?
Currently, no hedge funds are holding shares in ABVC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ABVC BioPharma, Inc.
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.
Technical Analysis
CervoMed
―
MindWalk Holdings
―
Jasper Therapeutics
―
MiNK Therapeutics
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
―
Insiders
1.36% Mutual Funds
0.14% Other Institutional Investors
97.09% Public Companies and
Individual Investors